-
Something wrong with this record ?
Phox2B is a sensitive and reliable marker of paraganglioma-Phox2B immunohistochemistry in diagnosis of neuroendocrine neoplasms
M. Manethova, L. Gerykova, H. Faistova, J. Drugda, M. Hacova, H. Hornychova, A. Ryska, F. Gabalec, J. Soukup
Language English Country Germany
Document type Journal Article
Grant support
NV19-01-00435
Ministerstvo Zdravotnictví Ceské Republiky
LM2018125
BBMRI-CZ
EF16_013/0001674
European Regional Development Fund-Project BBMRI-CZ.: Biobank network
DIAG
Univerzita Karlova v Praze
METD
Univerzita Karlova v Praze
NLK
ProQuest Central
from 2003-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2003-01-01 to 1 year ago
- MeSH
- Immunohistochemistry MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Carcinoma, Neuroendocrine * MeSH
- Neuroendocrine Tumors * diagnosis pathology MeSH
- Paraganglioma * diagnosis MeSH
- Transcription Factors analysis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Phox2B is a transcription factor responsible for chromaffin cell phenotype. Although it is used routinely for diagnosis of neuroblastoma, previous reports concerning its utility in the diagnosis of neuroendocrine neoplasms have been conflicting. We assessed Phox2b immunoreactivity in different neuroendocrine neoplasms. Tissue microarrays or whole sections of 36 paragangliomas (PGs), 91 well-differentiated neuroendocrine tumours of different organs (WDNETs), 31 neuroendocrine carcinomas (NECs), and 6 olfactory neuroblastomas (ONBs) were stained with Phox2B antibody (EP312) and GATA3. The percentage of positive cells and intensity was analysed using H-score. Phox2B immunoreactivity was seen in 97.2% (35/36) PGs, 11% (10/91) WDNETs, 9.7% (3/31) NECs, and 16.7% (1/6) ONBs. PGs were significantly more often positive (p < 0.001, χ2) than other neuroendocrine tumours, showing highest H-score (mean 144.9, SD ± 75.1) and percentage of positive cells (median 81.3%, IQR 62.5-92.5%). Compared to Phox2B-positive WDNETs, PGs showed significantly higher H-score (median 145 vs 7.5, p < 0.001) and percentage of positive cells (median 82.5% vs 4.5%, p < 0.001). Phox2B positivity was 97.2% sensitive and 89% specific for the diagnosis of PG. GATA3 was 100% sensitive and 88% specific for the diagnosis of PG. When combined, any Phox2B/GATA3 coexpression was 97.1% sensitive and 99.1% specific for the diagnosis of paraganglioma. Widespread Phox2B immunoreactivity is a highly characteristic feature of PGs and it can be used as an additional marker in differential diagnosis of neuroendocrine tumours.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010576
- 003
- CZ-PrNML
- 005
- 20240620143347.0
- 007
- ta
- 008
- 230718s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-023-03490-0 $2 doi
- 035 __
- $a (PubMed)36656393
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Manethova, Monika $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic
- 245 10
- $a Phox2B is a sensitive and reliable marker of paraganglioma-Phox2B immunohistochemistry in diagnosis of neuroendocrine neoplasms / $c M. Manethova, L. Gerykova, H. Faistova, J. Drugda, M. Hacova, H. Hornychova, A. Ryska, F. Gabalec, J. Soukup
- 520 9_
- $a Phox2B is a transcription factor responsible for chromaffin cell phenotype. Although it is used routinely for diagnosis of neuroblastoma, previous reports concerning its utility in the diagnosis of neuroendocrine neoplasms have been conflicting. We assessed Phox2b immunoreactivity in different neuroendocrine neoplasms. Tissue microarrays or whole sections of 36 paragangliomas (PGs), 91 well-differentiated neuroendocrine tumours of different organs (WDNETs), 31 neuroendocrine carcinomas (NECs), and 6 olfactory neuroblastomas (ONBs) were stained with Phox2B antibody (EP312) and GATA3. The percentage of positive cells and intensity was analysed using H-score. Phox2B immunoreactivity was seen in 97.2% (35/36) PGs, 11% (10/91) WDNETs, 9.7% (3/31) NECs, and 16.7% (1/6) ONBs. PGs were significantly more often positive (p < 0.001, χ2) than other neuroendocrine tumours, showing highest H-score (mean 144.9, SD ± 75.1) and percentage of positive cells (median 81.3%, IQR 62.5-92.5%). Compared to Phox2B-positive WDNETs, PGs showed significantly higher H-score (median 145 vs 7.5, p < 0.001) and percentage of positive cells (median 82.5% vs 4.5%, p < 0.001). Phox2B positivity was 97.2% sensitive and 89% specific for the diagnosis of PG. GATA3 was 100% sensitive and 88% specific for the diagnosis of PG. When combined, any Phox2B/GATA3 coexpression was 97.1% sensitive and 99.1% specific for the diagnosis of paraganglioma. Widespread Phox2B immunoreactivity is a highly characteristic feature of PGs and it can be used as an additional marker in differential diagnosis of neuroendocrine tumours.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 12
- $a neuroendokrinní nádory $x diagnóza $x patologie $7 D018358
- 650 _2
- $a transkripční faktory $x analýza $7 D014157
- 650 12
- $a paragangliom $x diagnóza $7 D010235
- 650 12
- $a neuroendokrinní karcinom $7 D018278
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Geryková, Lucie $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic $7 xx0318862
- 700 1_
- $a Faistova, Hana $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Drugda, Jan $u 4th Department of Internal Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Hacova, Maria $u Department of Pathology, The Regional Hospital Pardubice, Pardubice, Czech Republic
- 700 1_
- $a Hornychova, Helena $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Ryska, Ales $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Gabalec, Filip $u 4th Department of Internal Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Soukup, Jiri $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, 500 05, Hradec Králové, Czech Republic. 2jiri.soukup@gmail.com $1 https://orcid.org/0000000171694386
- 773 0_
- $w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 482, č. 4 (2023), s. 679-686
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36656393 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20240620143349 $b ABA008
- 999 __
- $a ok $b bmc $g 1963166 $s 1196841
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 482 $c 4 $d 679-686 $e 20230119 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a NV19-01-00435 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a LM2018125 $p BBMRI-CZ
- GRA __
- $a EF16_013/0001674 $p European Regional Development Fund-Project BBMRI-CZ.: Biobank network
- GRA __
- $a DIAG $p Univerzita Karlova v Praze
- GRA __
- $a METD $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20230718
